Global Product Liability Coverage for Indian Pharmaceutical Exporters

India exported pharmaceutical products worth approximately $27.8 billion in FY2025, making it the world's largest supplier of generic medicines by volume. The United States remains the single largest export destination, absorbing roughly $8.7 billion (31% of total exports), primarily generic drugs sold to retail pharmacy chains, hospital group purchasing organisations, and government procurement programmes including Medicaid and the Department of Veterans Affairs. The European Union collectively absorbed approximately $4.2 billion (15%), primarily through country-level tenders and hospital supply contracts. Africa, served largely through WHO-prequalified generics, accounted for approximately $3.8 billion (14%). Other significant markets include Southeast Asia, Latin America, and the Gulf Cooperation Council countries.

This export scale is supported by more than 3,000 US FDA-approved facilities in India and approximately 500 WHO-prequalified manufacturing sites. Indian generics account for roughly 40% of generic medicines sold in the US by volume. The country's position as the world's pharmacy is not contested; what is inadequately managed is the liability exposure that accompanies it.

The fundamental coverage gap is jurisdictional. A standard Indian product liability policy, issued by an Indian-registered insurer under the IRDAI licensing framework, covers liability claims arising under Indian law and adjudicated in Indian courts or arbitral tribunals. When a patient in New Jersey suffers an adverse reaction to an Indian-manufactured generic and files suit in the New Jersey Superior Court under the New Jersey Products Liability Act (NJPLA) and federal FDA standards, the Indian policy provides no coverage. The claim is governed by American law, adjudicated in an American court, and quantified in US dollars at American litigation value levels.

The scale of this exposure is material. US product liability verdicts against pharmaceutical manufacturers can reach hundreds of millions of dollars for multi-plaintiff litigation involving a single product. Even individual case settlements for adverse drug reactions commonly range from $250,000 to $2 million per plaintiff. A recalled product that has been distributed to tens of thousands of patients creates aggregate liability exposure in the hundreds of millions of dollars, exposure that no Indian domestic policy has been designed to cover. Indian pharma companies exporting to the US that rely only on their domestic product liability policy are exposed to catastrophic uninsured loss.

The jurisdictional limitation of Indian product liability policies is not an oversight; it reflects the structure of Indian insurance regulation. IRDAI licenses Indian insurers to operate in India, to write risks located in India, and to cover liabilities arising under Indian law. Indian insurers price their premiums on the basis of Indian claim frequency and severity data, under Indian claims handling and legal cost norms. Extending coverage to US or EU jurisdiction claims would expose them to liability patterns that are fundamentally different in both legal theory and quantum.

Indian product liability law is governed primarily by the Consumer Protection Act 2019, which established a three-tier consumer disputes resolution system (District, State, and National Commissions) and introduced the concept of product liability for the first time in explicit statutory form. Under Section 84 to 87 of the CPA 2019, a manufacturer is liable if the product causes harm and there is a manufacturing defect, a design defect, or a failure to warn. The maximum compensation awarded by the National Consumer Disputes Redressal Commission in a pharmaceutical case has historically been in the range of INR 25 to 75 lakh, with very few cases exceeding INR 1 crore. The legal costs in Indian PL litigation are similarly modest compared to US standards.

US pharmaceutical product liability operates under a fundamentally different regime. The learned intermediary doctrine, the preemption doctrine (as developed by the US Supreme Court in Wyeth v. Levine, 2009, and Pliva v. Mensing, 2011), and state-specific product liability laws create a complex legal environment where the outcome of any given case is difficult to predict. For generic manufacturers, the Mensing decision established that generic manufacturers are generally protected from failure-to-warn claims because their labels must match the brand manufacturer's label, but the preemption shield has limits and is still being litigated in specific factual contexts. The point for insurance purposes is that US litigation value is determined by American jury norms, American legal costs ($1,500 to $3,000 per hour for specialised pharmaceutical defence counsel), and American settlement dynamics, none of which are reflected in Indian policy pricing.

EU pharmaceutical liability is governed by the EU Product Liability Directive 85/374/EEC, implemented in each member state's national law, and the EU General Product Safety Regulation (GPSR) 2023, which strengthened market surveillance and recall obligations. EU PL claims are generally less severe than US claims in quantum because punitive damages are not available and contingency fee arrangements for plaintiff attorneys are less common. However, the EU framework includes strict liability (no need to prove negligence, only that the product was defective and caused harm), and the administrative costs of responding to a European Medicines Agency (EMA) or national competent authority investigation following a product recall can be substantial. UK PL post-Brexit follows a parallel framework under the Consumer Protection Act 1987.

South African, Nigerian, and Kenyan markets, where Indian generics have significant penetration, operate under their respective national product liability laws. South Africa's Consumer Protection Act 68 of 2008 imposes strict liability on suppliers in the supply chain. These African jurisdiction claims are less frequently covered even by international product liability programmes, which often exclude or sub-limit Africa as a market.

The US Food and Drug Administration's import alert mechanism is one of the most significant regulatory tools affecting Indian pharma's US business. An FDA import alert directs US Customs and Border Protection to detain or refuse entry to products from a specific manufacturer or country of origin without physical examination, on the basis that the products appear to violate FDA requirements. As of April 2026, the FDA's import alert database contains approximately 185 alerts specifically naming Indian pharmaceutical manufacturing facilities or products, making India one of the countries most frequently subject to import alerts in the pharmaceutical category.

An import alert creates three categories of insurance-relevant cost. The direct cost is the loss of US sales during the alert period: a facility subject to import alert may be unable to supply its US customers for months or years while it addresses the underlying quality system deficiencies and seeks FDA clearance. A major Indian generic manufacturer relying on a single facility for its US business could lose $150 to $300 million in annual revenue if that facility is placed under import alert. Business interruption coverage for this scenario is available from international markets but is expensive and sub-limited.

The recall cost is the second category. When a product already in the US market is recalled because of a quality defect discovered through FDA inspection, post-market surveillance, or adverse event reports, the recall costs include product retrieval logistics, notification to healthcare providers and patients, laboratory testing of retained samples, regulatory correspondence costs, and the potential cost of replacement product supplied at no charge. US product recall costs for a national recall of a generic drug distributed through 30,000 pharmacies can exceed $5 to 15 million in direct recall expenses alone, before any third-party liability claims are considered.

The third-party liability cost follows when the defective product causes patient harm. The FDA's MedWatch system and mandatory adverse event reporting requirements (under 21 CFR Part 314 for prescription drugs) ensure that adverse events are documented and can be used in subsequent civil litigation. If an FDA inspection found specific manufacturing deficiencies before or contemporaneously with a product recall, plaintiff attorneys will use those inspection records in civil litigation to establish that the manufacturer knew or should have known of the quality problems. The FDA Form 483 observations and Warning Letters that preceded a recall become exhibit A in the plaintiff's case.

Indian pharma exporters to the US need coverage that responds to all three cost categories: revenue loss from import alert, direct recall costs, and third-party liability for harm caused by recalled products. These three categories typically sit across different policies (business interruption, product recall expense, product liability), and coordinating them requires a global insurance programme structure rather than a collection of standalone domestic policies. ICICI Lombard's global pharmaceutical programme explicitly addresses the import alert scenario, with specified coverage triggers tied to FDA import alert issuance and a defined claims process for revenue loss quantification.

WHO prequalification is a quality certification issued by the World Health Organisation that certifies a medicine as meeting international standards of safety, efficacy, and quality. It is a condition of supply for most international procurement agencies (UNICEF, Global Fund, PEPFAR, Médecins Sans Frontières) and for government health ministries in many African, Asian, and Latin American countries that use WHO prequalification as a substitute for their own local registration process.

Approximately 80 Indian pharmaceutical companies hold WHO prequalification for at least one product as of 2026, covering primarily antiretrovirals, antimalarials, tuberculosis treatments, and maternal and child health medicines. The WHO prequalification market is critical for Indian pharma's Africa business: Indian manufacturers supply approximately 70% of WHO-prequalified generics consumed by Global Fund-supported programmes.

When a WHO prequalification lapses or is suspended, the insurance-relevant consequences are significant. First, the manufacturer becomes ineligible for WHO-prequalified procurement contracts, which may represent 30 to 60% of the revenue from the affected product. Second, health ministries in countries relying on WHO prequalification may be required to recall products already in their supply chains, creating a recall liability event. Third, UNICEF and Global Fund may seek recovery of advance payments for products that cannot be delivered because of the prequalification lapse.

WHO prequalification lapses occur for several reasons: failure to submit timely data updates to WHO, manufacturing site changes that require requalification, inspection findings during WHO surveillance inspections, and changes to the reference medicine's formulation or quality standards. Indian manufacturers have experienced prequalification lapses that resulted in contract cancellations and revenue losses of $10 to 50 million in individual cases.

Covering prequalification lapse risk requires careful policy design. A standard product liability policy does not respond to prequalification lapse because there is no third-party claim for bodily injury or property damage; the loss is commercial. Commercial credit insurance or supply contract disruption insurance, not product liability, is the relevant product for the revenue loss component. However, if the prequalification lapse follows a quality finding that also generated patient adverse events, the product liability exposure becomes real. Indian pharma exporters with significant WHO prequalification-dependent revenue need to separately assess and cover three distinct exposures: revenue loss from procurement disqualification, product recall costs from market withdrawals required by health ministries, and third-party liability from patient harm associated with the quality finding.

Indian pharmaceutical exporters selling into the US, UK, and EU markets face contractual insurance requirements specified in their supply agreements. These requirements are not optional: failure to maintain the specified coverage is typically a breach of the supply agreement that entitles the buyer to terminate the contract. The limits required by different buyer categories reflect their assessment of the liability they face if an Indian supplier's product causes harm.

US hospital group purchasing organisations (GPOs) and large retail pharmacy chains (CVS, Walgreens, Rite Aid distribution programmes) typically require a minimum of $10 million per occurrence and $20 million aggregate product liability coverage from generic drug suppliers, with the GPO or pharmacy chain named as an additional insured on the policy. Some large GPOs representing federal health programmes (Vizient, Premier, Intalere) require $25 million per occurrence for controlled substances or products with higher adverse event risk profiles. These limits must be evidenced by certificates of insurance showing a US-admitted insurer (licensed in the relevant state) or a non-admitted insurer with an AM Best rating of at least A- and a financial strength category of at least X.

EU pharmaceutical distributors and hospital supply chains typically require minimum product liability coverage of EUR 5 to 10 million per occurrence, provided under a policy that covers EU jurisdiction claims. The EU GPSR 2023 increases the documentation obligations on suppliers and may lead to higher contractual insurance requirements over the next 2 to 3 years as distributors update their standard supply terms to reflect the new regulation's increased liability exposure.

WHO and international procurement agencies generally do not specify minimum insurance limits in their prequalification conditions or procurement contracts, but they reserve the right to seek indemnification from suppliers for costs incurred due to product quality failures, including recall costs and replacement supply costs. Experienced procurement lawyers advise Indian suppliers to maintain product recall expense coverage of at least $5 million and product liability coverage of at least $10 million for WHO-prequalified product lines, even absent a specific contractual requirement.

Retail pharmacy chains in the UK post-Brexit now operate under the UK Conformity Assessed (UKCA) framework for product safety and may require evidence of coverage under a UK-admitted policy or under a Lloyd's of London policy, which is recognised across the UK market regardless of Lloyd's syndicates' non-admission status. The minimum limits for UK pharmacy supply agreements are typically GBP 5 million per occurrence, though this varies by product category and buyer.

Indian pharma exporters should review their existing supply agreements against the coverage actually carried. In many cases, Indian companies carry domestic PL coverage in the range of INR 5 to 25 crore (approximately $600,000 to $3 million), which is well below the minimum required by US GPO contracts. The gap between the coverage carried and the coverage required creates a breach of contract risk on top of the underlying uninsured liability risk.

Structuring global product liability coverage for an Indian pharma exporter requires a choice between two primary architectural approaches: local admitted policies in each export market, and difference in conditions (DIC) coverage over a domestic primary policy.

Local admitted policies are product liability policies issued by insurers licensed in the target jurisdiction (a US-admitted insurer for US coverage, an FCA-authorised insurer for UK coverage, an insurer authorised under the EU Solvency II framework for EU coverage). The advantages of local admitted policies are regulatory recognition (they satisfy the buyer's insurance requirements without question), local claims handling (the insurer's claims team operates within the same legal system as the claim), and local legal currency (the policy is denominated in the currency of the jurisdiction, eliminating FX translation issues in settlement). The disadvantages are cost (purchasing separate admitted policies in five or six markets is more expensive than a single global programme), complexity (multiple insurers, multiple renewal dates, multiple policy wordings), and gaps (coverage conditions may differ between policies, creating coordination problems when a single product event triggers claims in multiple jurisdictions).

DIC (Difference in Conditions) coverage is an international policy that sits above a primary domestic policy and covers losses in foreign jurisdictions that the primary domestic policy does not cover. The DIC policy defines the scope of coverage it provides, typically aligning to the broader of the local market coverage standard and filling gaps versus the domestic primary. In the pharma context, a DIC programme would sit above the Indian domestic product liability policy and provide coverage for US, EU, UK, and African jurisdiction claims that the Indian primary policy excludes. The advantages of DIC are administrative simplicity, consolidated global limits, and single renewal management. The disadvantages are buyer acceptance (some US buyers require explicitly admitted coverage rather than accepting a DIC structure) and claims coordination complexity (the primary and DIC insurers must agree on the scope of their respective obligations when a claim arises).

For Indian pharma exporters to the US, the practical constraint is that many US buyers explicitly require US-admitted coverage, which effectively mandates a local admitted policy for the US market. A hybrid structure is therefore common: an admitted US policy from a surplus lines carrier or an International insurer with US admitted status (Zurich, AIG, Chubb, or Berkley), plus a DIC policy covering EU, UK, and other international jurisdictions, plus the Indian domestic primary for India-jurisdiction claims.

ICICI Lombard, through its partnership with a Lloyd's syndicate for international risks, offers Indian pharma exporters a coordinated global programme that includes an Indian primary policy, Lloyd's-based coverage for the US market through a non-admitted carrier (acceptable to many mid-market US buyers if the AM Best rating threshold is met), and DIC coverage for EU and UK. New India Assurance, as a government-owned insurer with treaty relationships with several international partners, offers a parallel structure that some government pharma procurement entities (notably those purchasing for defence and public health programmes) find preferable because of New India's sovereign backing.

The total premium for a comprehensive global product liability programme for an Indian generic manufacturer exporting $100 million annually to the US, EU, and Africa typically ranges from $800,000 to $2.5 million annually, depending on the product risk profile (oncology products at the higher end, off-patent antibiotics at the lower end), prior loss history, and the coverage structure. This represents a significant insurance cost, but it is proportionate to the liability exposure on a $100 million export business.

Pricing global product liability coverage for Indian pharmaceutical exporters is driven by four primary underwriting factors: the risk profile of the product portfolio (therapeutic category and associated adverse event history), the export market mix (US exposure commands the highest premium loading), the insured's regulatory compliance record (FDA inspection history, warning letters, import alerts), and the manufacturing quality management system (GMP certification, track record of site inspections, corrective action completion rates).

Product risk profile has the most influence on pricing. Oncology products, immunosuppressants, and anticoagulants carry significantly higher product liability premium rates than antibiotics, vitamins, and over-the-counter analgesics, because adverse events with high-risk drugs are more frequent, more severe, and more likely to result in litigation. A generic oncology manufacturer exporting to the US pays 3 to 5 times the rate per million dollars of coverage that an OTC analgesic manufacturer pays for equivalent coverage structures.

US exposure weighting increases premium substantially. A programme covering US sales pays approximately 60 to 70% of its total global premium for the US component, reflecting the higher litigation frequency and severity in the US market compared to EU and other markets. Insurers writing Indian pharma product liability typically charge 0.15 to 0.45% of US annual sales revenue as the US product liability premium component, depending on the product risk profile and compliance record. EU coverage premiums are approximately 40 to 60% of the US rate for equivalent limits.

FDA inspection record is a significant rating factor. A manufacturer with a clean recent FDA inspection record (no 483 observations outstanding, no warning letters in the preceding 3 years, no import alerts) is rated more favourably than one with a history of FDA quality findings. Underwriters request copies of recent FDA inspection reports as part of the underwriting submission. A manufacturer currently subject to an FDA warning letter for a facility supplying US markets may face coverage exclusions for claims arising from products from that specific facility, or may be unable to obtain coverage for US market claims from that facility at all until the warning letter is resolved.

Claims history in the preceding 5 years affects pricing through experience rating. An Indian pharma exporter with prior US product liability claims (even if settled for amounts below policy limits) will face higher renewal premiums or more restrictive coverage conditions. Insurers writing Indian pharma PL have observed an increase in US class action exposures as plaintiff attorneys have become more active in pursuing generic manufacturer claims since the opioid litigation demonstrated the plaintiff bar's capacity to pursue pharmaceutical manufacturers aggressively.

The most significant recent claims trend affecting Indian pharma coverage is the nitrosamine contamination issue. Since 2018, the FDA has required recalls of several generic drug products (valsartan, ranitidine, losartan, metformin) from multiple Indian manufacturers due to detection of nitrosamine impurities above acceptable daily intake limits. These recalls generated product recall expense claims and, in some cases, third-party liability claims from patients who alleged harm from nitrosamine exposure. The nitrosamine experience has made underwriters more attentive to the API sourcing and manufacturing process controls of Indian pharma clients, and has introduced API impurity risk as an explicit underwriting question in Indian pharma PL submissions.